In responding to the unprecedented COVID-19 challenges, companies around the world are rushing to capitalize on the current crisis by advertising the effectiveness of their products in containing the virus spread. Among these ads and messages, some may be useful in building the public’s confidence and marketing effective products to consumers, but some may mislead and deceive desperate consumers into buying treatments and products without any scientific support. As fear and anxiety proliferate during this pandemic, fraudulent or false advertisements also surge and explode. Petitioners raise false advertising claims and try to stop misleading advertisements by seeking injunctions. However, the injunction standard in the false advertising context is still the subject of debate.
Recent Posts
- NIH Intramural Licensing Guidelines Hit the Wrong Note at the Wrong Time
- Other Barks & Bites for Friday, July 19: UPC Issues First-Ever Patent Revocation; Meta Announces Latest AI Model Won’t be Released in EU Due to Regulatory Concerns; and CAFC Dismisses PTAB Appeal as Moot Due to Prior District Court Invalidation
- Federal Circuit Affirms Ineligibility of Background Check Patent Claims
- The Administrative Procedure Act and Its Impact on Intellectual Property
- USPTO Updates Eligibility Guidance for AI: ‘We Want to Accelerate AI Innovation Without Locking it Up’